日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

MRD-driven phase 2 study of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma

一项以微小残留病灶（MRD）为导向的2期临床研究，评估达雷妥尤单抗、卡非佐米、来那度胺和地塞米松联合治疗新诊断多发性骨髓瘤的疗效

期刊:Blood Advances
影响因子:7.1
doi:10.1182/bloodadvances.2024014417
Bhutani, Manisha; Robinson, Myra; Foureau, David; Atrash, Shebli; Paul, Barry; Guo, Fei; Grayson, Jason M; Ivanina-Foureau, Anna; Pineda-Roman, Mauricio; Varga, Cindy; Friend, Reed; Ferreri, Christopher J; Begic, Xhevahire; Norek, Sarah; Drennan, Tiffany; Anderson, Michelle B; Symanowski, James T; Voorhees, Peter M; Usmani, Saad Z
多发性骨髓瘤
骨髓瘤
发表日期：2025
文献求助 收藏

Efficacy of Selinexor in Relapsed/Refractory Multiple Myeloma (RRMM) Patients with del17p and Other High-Risk Abnormalities (A Retrospective Single-Center Study)

Selinexor治疗伴有del17p和其他高危异常的复发/难治性多发性骨髓瘤（RRMM）患者的疗效（一项回顾性单中心研究）

期刊:Life-Basel
影响因子:3.4
doi:10.3390/life14030384
Ehsan, Hamid; Robinson, Myra; Voorhees, Peter M; Cassetta, Kristen; Borden, Shanice; Atrash, Shebli; Bhutani, Manisha; Varga, Cindy; Pineda-Roman, Mauricio; Friend, Reed; Paul, Barry A
多发性骨髓瘤
骨髓瘤
发表日期：2024
文献求助 收藏

Eight-year median survival in multiple myeloma after total therapy 2: roles of thalidomide and consolidation chemotherapy in the context of total therapy 1

多发性骨髓瘤患者接受全疗程 2 后 8 年中位生存期：沙利度胺和巩固化疗在全疗程 1 中的作用

期刊:British Journal of Haematology
影响因子:3.8
doi:10.1111/j.1365-2141.2008.06982.x
Zangari, Maurizio; van Rhee, Frits; Anaissie, Elias; Pineda-Roman, Mauricio; Haessler, Jeff; Crowley, John; Barlogie, Bart
多发性骨髓瘤
骨髓瘤
发表日期：2008
文献求助 收藏

Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2

在多发性骨髓瘤患者中，硼替佐米治疗3期可带来持续完全缓解：与2期治疗的比较

期刊:British Journal of Haematology
影响因子:3.8
doi:10.1111/j.1365-2141.2007.06921.x
Pineda-Roman, Mauricio; Zangari, Maurizio; Haessler, Jeff; Anaissie, Elias; Tricot, Guido; van Rhee, Frits; Crowley, John; Shaughnessy, John D Jr; Barlogie, Bart
多发性骨髓瘤
骨髓瘤
发表日期：2008
文献求助 收藏

Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis

多发性骨髓瘤中出现的良性单克隆丙种球蛋白病基因表达特征与良好的预后相关。

期刊:Blood
影响因子:23.1
doi:10.1182/blood-2006-07-037077
Zhan, Fenghuang; Barlogie, Bart; Arzoumanian, Varant; Huang, Yongsheng; Williams, David R; Hollmig, Klaus; Pineda-Roman, Mauricio; Tricot, Guido; van Rhee, Frits; Zangari, Maurizio; Dhodapkar, Madhav; Shaughnessy, John D Jr
多发性骨髓瘤
骨髓瘤
发表日期：2007
文献求助 收藏

Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation.

通过荧光原位杂交检测到浆细胞疾病中 1q21 染色体带的频繁获得：从 MGUS 到复发性骨髓瘤，发生率增加，并且与串联干细胞移植后的预后和疾病进展有关

期刊:Blood
影响因子:23.1
doi:10.1182/blood-2006-03-009910
Hanamura Ichiro, Stewart James P, Huang Yongsheng, Zhan Fenghuang, Santra Madhumita, Sawyer Jeffrey R, Hollmig Klaus, Zangarri Maurizio, Pineda-Roman Mauricio, van Rhee Frits, Cavallo Federica, Burington Bart, Crowley John, Tricot Guido, Barlogie Bart, Shaughnessy John D Jr
发育与干细胞
细胞生物学
骨髓瘤
发表日期：2006
文献求助 收藏